Sit in on enough appointments and you will notice gabapentin everywhere, handed out for anxiety, for sleep, for back pain, for restless legs, for more or…
Sections
Sit in on enough appointments and you will notice gabapentin everywhere, handed out for anxiety, for sleep, for back pain, for restless legs, for more or less anything that nags, and most of the people taking it have no idea that for a lot of those uses the evidence underneath is thin to nonexistent. It started life as an epilepsy drug, it goes by the brand name Neurontin, and it climbed to one of the most prescribed medications in the country not because the science kept widening but because it was marketed, hard and at one point illegally, into territory it was never proven to help. That history is worth knowing, because it explains why a drug a lot of people treat as a harmless catch-all is at the same time more useful and more problematic than its easygoing reputation lets on.
The drug that got sold
The reason gabapentin sits in so many medicine cabinets is not a stack of trials, it is a marketing campaign that turned into a landmark legal case. The company behind Neurontin ran an off-label promotion machine through the 1990s, working the literature and the prescriber world to plant the idea that it helped with pain and bipolar and anxiety and a long menu of conditions it had never been approved for, and a careful review of the internal company documents later spelled out exactly how that was pulled off (Steinman 2006, PMID 16908919). The case ended in a giant settlement, but by then the prescribing reflex was set, and a good chunk of the off-label use we still see is the long tail of a sales push rather than of any real body of proof.
What it actually treats, and what it only might
On paper gabapentin is approved for a narrow slice, as an add-on for certain seizures and for the nerve pain that lingers after a shingles infection, and that is roughly where the ground is solid. For chronic nerve pain more broadly the data is real but modest, it helps a fraction of people and rarely dramatically (Wiffen 2017, PMID 28597471). Step past that and you are in off-label country, where it gets reached for in generalized anxiety, insomnia, alcohol withdrawal, even hot flashes, and the fair summary of the psychiatric evidence is that most of it is low quality and inconsistent, a few signals worth taking seriously floating in a sea of weak studies (Berlin 2015, PMID 26835178). That is not the same as useless, there are real off-label spots where reaching for it is defensible, but it does mean the confidence with which the drug gets handed out runs miles ahead of what anybody has actually shown.
Where it genuinely earns its place
There are situations where gabapentin is a smart call, and they have a pattern. Genuine neuropathic pain is the clearest one. The jittery, sleepless, anxious early stretch of alcohol withdrawal and getting sober is another, where it has a legitimate and growing role and the real advantage of not being a benzodiazepine. And for a certain body-based flavor of anxiety, the racing, cannot-settle, cannot-sleep kind, some people get honest relief from it when other things missed. The thread running through all of those is that gabapentin tends to work for pain and for anxiety that lives in the body, and tends to disappoint when it is being used as a vague all-purpose calm-down pill for a problem it was never going to fit.
Wide range, built up slowly
Often started low and titrated, anywhere from a few hundred milligrams a day up into the thousands depending on what it is treating, split into two or three doses because it clears fast. The dose comes down if your kidneys are not in good shape.
Builds over days, not a rescue
For pain and anxiety the real effect builds over days to weeks at a proper dose. The drowsy hit some people chase is not the same thing as the therapeutic benefit, and treating it like a knockout pill is how trouble starts.
Taper, do not quit cold
Stopping a meaningful dose abruptly can bring a real withdrawal, the anxiety and sweating and insomnia and, at the extreme, seizures, so you ramp it down on a plan rather than dropping it overnight.
The part the easygoing reputation skips
What gets lost when a drug is treated as harmless is that gabapentin is not as clean as it looks. It carries genuine abuse and diversion potential, especially among people who also use opioids, where it can amplify the high and has been turning up in overdose deaths, a pattern a systematic review pulled together out of the literature (Smith 2016, PMID 27265421). It also has a real withdrawal once you have been on a decent dose for a while and stop suddenly, which blindsides people who were told the stuff was benign, since the anxiety and the insomnia it was supposedly treating come back louder than before. None of that puts it in the danger class of the drugs it sometimes gets handed out to replace, but it does mean the casual, refill-it-forever, nobody-is-really-watching way it tends to get used is a mistake worth catching.
The honest read
Gabapentin is a genuinely useful drug trapped inside an inflated reputation, and both halves of that are true at once. Pointed at what it actually treats, the neuropathic pain, the alcohol-withdrawal stretch, that specific body-anxiety niche, it is a reasonable and often non-habit-forming option, and not being a benzodiazepine is a real mark in its favor for the right person. Used the way it too often is, as a default sprinkle on any complaint that carries the word anxiety or pain, it is thin medicine hauling more downside than the person prescribing it usually admits. If it shows up on your list, the questions worth asking are dead simple, what exactly is it for, is that one of the things it has actually been shown to help, and what is the plan for coming off it, and if nobody can answer those cleanly, that gap is worth noticing.
Sources
- Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145(4):284-293. PMID 16908919.
- Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD007938. PMID 28597471.
- Berlin RK, Butler PM, Perloff MD. Gabapentin Therapy in Psychiatric Disorders: A Systematic Review. Prim Care Companion CNS Disord. 2015;17(5). PMID 26835178.
- Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160-1174. PMID 27265421.
- FDA prescribing information for gabapentin (Neurontin) via DailyMed, the source for the approved seizure and postherpetic-neuralgia indications, the dosing and renal adjustment, and the discontinuation guidance in this piece.
